Medical Statistics has never been easier!

David E. Matthews
Vernon T. Farewell

Using and Understanding Medical Statistics
5th, revised and extended edition

The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the 'heavy lifting'.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis, and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents
Preface to the Fifth Edition
Prefaces to the Previous Editions
• Basic Concepts
• Tests of Significance
• Fisher’s Test for 2×2 Contingency Tables
• Approximate Significance Tests for Contingency Tables
• Some Warnings concerning 2×2 Tables
• Kaplan-Meier or ‘Actuarial’ Survival Curves
• The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
• An Introduction to the Normal Distribution
• Analyzing Normally Distributed Data
• Linear Regression Models for Medical Data
• Binary Logistic Regression
• Regression Models for Count Data
• Proportional Hazards Regression
• The Analysis of Longitudinal Data
• Analysis of Variance
• Data Analysis
• The Question of Sample Size
• The Design of Clinical Trials
• Further Comments regarding Clinical Trials
• Meta-Analysis
• Epidemiological Applications
• Diagnostic Tests
• Agreement and Reliability
References
Subject Index

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f +41 61 306 12 34
www.karger.com

MATTHEWS, D.E. (Waterloo, Ont.);
FAREWELL, V.T. (Cambridge)
Using and Understanding Medical Statistics
5th, revised and extended edition
XX + 338 p., 48 fig., 103 tab., 2015
CHF 49.00 / EUR 46.00 / USD 54.00
(hard cover + online supplementary material)
Online version for institutional purchase
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for USA and Latin America only
(hard cover + online supplementary material)

The easiest way to order: www.karger.com/medical_statistics

Downloaded by: 54.70.40.11 - 1/6/2018 10:13:01 PM
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy

Founded 1959 as 'Chemotherapia' by H.P. Kuehmerle and P. Rentchnick

Editor-in-Chief
G. Minotti, Rome

Associate Editors
G. Delogu, Rome
G. Graziani, Rome

Editorial Board
A.M. Biroccio, Rome
C. Chiesa, Rome
S. Gemma, Siena
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
P. Linder, Geneva
K. Machka, Munich
P. Menna, Rome
E. Monti, Busto Arsizio
K.G. Naber, Straubing
R. Nau, Göttingen
P. Preziosi, Rome
E. Salvatorelli, Rome
M. Sanguinetti, Rome
G. Sava, Trieste
G.M. Shah, Quebec, Que.
F. Sörgel, Nuremberg-Heroldsberg
J.C. Stingl, Bonn
F. Van Bambeke, Brussels
M. Wilhelm, Nuremberg

Paul Ehrlich
1854–1915
The founder of chemotherapy

Printed in Germany on acid-free and non-aging paper
(ISO 9706) by Stückle Druck, Ettenheim
Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion, discretion(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.


In case of problems with submission, please contact:
che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approved the manuscript submission. Submission of an article implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of the author. The Editors reserve the rights to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures should be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Figures and tables should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ™ or ® when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PDF, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Color Illustrations

Online edition: Color figures are reproduced free of charge.

In the print version, the figures are reproduced in black and white. Referring to colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References

Identity references in the text using Arabic numerals [in square brackets]. Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the references. Authors' surnames should be followed by their initials with no punctuation or hyphenation. Do not use punctuation or hyphenation to separate individual authors. Preferably cite all authors (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website (see: http://www.nlm.nih.gov). International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables must have titles and legends and all files must be supplied separately and named clearly. Acceptable files and formats are Word or PDF files, Excel spreadsheets (if the data cannot be converted properly to a PDF file), and multimedia files (MPEG, AVI or QuickTime formats).

English Language Editing

For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)

A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access

Karger authors are encouraged to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

   ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final published version will be available at http://www.karger.com/doi [insert DOI number].’

- Be linked to the final version on www.karger.com
- Follow the terms of the relevant Creative Commons license.
- Be linked to the final version on www.karger.com
- Include the following statement:

   ‘The final, published version of this article is available at http://www.karger.com/doi [insert DOI number].’

It is the author’s responsibility to fulfill these requirements. For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

Copy Editing

Authors are responsible for the accuracy of their manuscript and can request a professional language editing service prior to submission. For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Proofs

An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges

There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints

An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
1 Editorial
Minotti, G.; Graziani, G.; Delogu, G. (Rome)

Antimicrobial Section

Original Papers

3 Safety and Outcome of Pharmacy-Led Vancomycin Dosing and Monitoring
Momattin, H.; Zogheib, M.; Homoud, A. (Dhahran); Al-Tawfiq, J.A. (Dhahran/Indianapolis, Ind.)

8 Biofilm Formation and Susceptibility to Polymyxin B by a Highly Prevalent Clone of Multidrug-Resistant Acinetobacter baumannii from a Mexican Tertiary Care Hospital
Rosales-Reyes, R.; Alcántar-Curiel, M.D.; Jarillo-Quijada, M.D.; Gayosso-Vázquez, C. (Mexico City); Morfin-Otero, M.d.R.; Rodríguez-Noriega, E. (Guadalajara); Santos-Preciado, J.I. (Mexico City)

Anticancer Section

Original Papers

15 A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study
Selle, F. (Paris); Pautier, P.; Lhommé, C. (Villejuif); Viens, P. (Marseille); Fabbro, M. (Montpellier); LokieC, F. (Saint-Cloud); Gligorov, J.; Richard, S.; Provent, S.; Soares, D.G.; Lotz, J.-P. (Paris)

23 Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

32 Fabrication of Alginate/Calcium Carbonate Hybrid Microparticles for Synergistic Drug Delivery
Peng, Y.; Sun, H.-Y.; Wang, Z.-C.; Xu, X.-D.; Song, J.-C.; Gong, Z.-J. (Wuhan)

41 Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

51 Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
Azadeh, P.; Mortazavi, N.; Tahmasebi, A. (Tehran); Hosseini Kamal, F. (Gothenburg); Novin, K. (Tehran)